预防中风的药物治疗方法
Nimisha Shaji1, Robert F Storey2, William A E Parker3
1Final Year Medical Student.
The British journal of cardiology
|September 9, 2024
概括
预防中风包括管理风险因素,如口服抗凝药的心房动和抗血小板治疗的动脉样性心血管疾病. 综合评估和治疗是减少中风发生率及其影响的关键.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 预防医学 预防医学
背景情况:
- 脑卒中是导致死亡,残疾和经济负担的主要原因.
- 了解不同类型的中风 (血栓性,栓塞性,出血性) 对于有效预防至关重要.
- 关键的危险因素包括心房动,动脉样硬化心血管疾病,高血压,脂质失调和糖尿病.
研究的目的:
- 为预防中风概述综合战略.
- 强调风险因素修改的重要性.
主要方法:
- 审查目前关于中风预防疗法的指导方针和证据.
- 讨论药理干预措施,包括口服抗凝药和抗血小板治疗.
- 突出血压,脂质和血糖控制的作用.
主要成果:
- 建议口服抗凝药用于心房动/心房动的患者.
- 抗血小板治疗适用于已确诊的动脉样硬化心血管疾病的患者.
- 强化抗血小板治疗或联合治疗可以进一步降低缺血性中风风险,但会增加出血风险.
- 血压,脂质和血糖控制是必不可少的.
- 炎症是预防中风的新兴目标.
结论:
- 对风险因素的全面评估和药理管理是预防中风的核心.
- 根据中风类型和患者的风险因素定制治疗方法至关重要.
- 正在进行的针对炎症等新目标的研究可能会为未来的预防策略提供帮助.
相关概念视频
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Anticoagulant Drugs: Low-Molecular-Weight Heparins
652
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
652
Drug Therapy
40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
40
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398


